- Home
- TRDA vs VALN Comparison
TRDA vs VALN Comparison
Compare TRDA & VALN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRDA
- VALN
- Stock Information
- Founded
- TRDA 2016
- VALN 2012
- Country
- TRDA United States
- VALN France
- Employees
- TRDA N/A
- VALN N/A
- Industry
- TRDA Biotechnology: Pharmaceutical Preparations
- VALN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TRDA Health Care
- VALN Health Care
- Exchange
- TRDA Nasdaq
- VALN Nasdaq
- Market Cap
- TRDA 502.9M
- VALN 510.7M
- IPO Year
- TRDA 2021
- VALN 2021
- Fundamental
- Price
- TRDA $8.13
- VALN $6.79
- Analyst Decision
- TRDA Strong Buy
- VALN Strong Buy
- Analyst Count
- TRDA 3
- VALN 2
- Target Price
- TRDA $25.67
- VALN $16.00
- AVG Volume (30 Days)
- TRDA 168.7K
- VALN 142.9K
- Earning Date
- TRDA 05-06-2025
- VALN 05-06-2025
- Dividend Yield
- TRDA N/A
- VALN N/A
- EPS Growth
- TRDA N/A
- VALN N/A
- EPS
- TRDA 1.68
- VALN N/A
- Revenue
- TRDA $210,782,000.00
- VALN $175,564,758.00
- Revenue This Year
- TRDA N/A
- VALN $19.17
- Revenue Next Year
- TRDA N/A
- VALN $26.31
- P/E Ratio
- TRDA $4.84
- VALN N/A
- Revenue Growth
- TRDA 63.38
- VALN 10.32
- 52 Week Low
- TRDA $7.10
- VALN $3.62
- 52 Week High
- TRDA $21.79
- VALN $9.50
- Technical
- Relative Strength Index (RSI)
- TRDA 35.90
- VALN 50.63
- Support Level
- TRDA $7.56
- VALN $6.54
- Resistance Level
- TRDA $8.72
- VALN $7.30
- Average True Range (ATR)
- TRDA 0.66
- VALN 0.48
- MACD
- TRDA 0.07
- VALN 0.01
- Stochastic Oscillator
- TRDA 44.02
- VALN 56.79
About TRDA Entrada Therapeutics Inc.
Entrada Therapeutics Inc clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient delivery of a wide range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. Its pipeline includes solutions for Neuromuscular Disease, Beyond Neuromuscular, and Platform Expansion.
About VALN Valneva SE
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.